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Summary
Background: Patient-reported outcomes (PROs) such as health-related quality of life 
(HRQoL) and symptoms associated with chronic hepatitis B viral (HBV) infection have 
not been well-described in North American cohorts.
Aims: To evaluate several PROs and associations with HBV disease activity markers.
Methods: Cross-sectional analysis including 876 adults who completed PRO measures 
during the Hepatitis B Research Network Adult Cohort Study. Participants on HBV 
treatment were excluded. Outcomes included: HRQoL using the SF-36 mental com-
ponent summary and physical component summary scores; symptom burden using a 
10-item Total Symptom Checklist and fatigue using an instrument from the Patient-
Reported Outcomes Measurement Information System®. Covariates included labora-
tory markers of disease severity, virological status, comorbidities and medications.
Results: Median age was 42 (range: 19-79), 51% were female, 73% Asian, 19% HBeAg 
(+), 2% had AST-platelet ratio index (APRI) ≥1.5 and 74% without comorbidities. Mean 
mental component summary T-score = 52, physical component summary T-score = 54 
and PROMIS Fatigue T-score = 47. On a scale from 0 (none) to 40 (extreme), the mean 
Symptom Checklist score = 3 and 25% reported no symptoms. The most frequent 
symptoms were fatigue (60%), irritability (32%) and itching (32%). Most symptoms 
were ‘a little bit’ bothersome. In multivariable regressions, APRI ≥1.50 and more co-
morbidities were associated with worse patient-reported outcomes; virological mark-
ers were not. Adding the Total Symptom Checklist score to original regression models 
increased explanation of variation in the mental component summary score from 4% 
to 44% and the Physical Component Summary Score from 17% to 34%.
Conclusions: Untreated North American HBV patients with mild liver disease report 
favourable health-related quality of life and minimal symptoms. HBV does not impact 
health-related quality of life unless advanced liver disease or comorbidities are pre-
sent. High symptom burden explains substantial variation in health-related quality of 
life. (CT.gov identifier: NCT01263587).
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1  | INTRODUC TION
Chronic hepatitis B viral (HBV) infection affects over one million 
people living in the United States and Canada and is estimated to 
lead to advanced cirrhosis or liver cancer in 10% of infected indi-
viduals.1 Health-related quality of life (HRQoL) refers to patients’ 
perceptions of their overall health status, including their physical, 
mental, psychological and social functioning and ability to engage 
in life activities and responsibilities. Several studies have demon-
strated that HRQoL may be compromised in patients chronically 
infected with HBV compared to population controls.2 Decrements 
in HRQoL are often associated with liver disease severity, such that 
patients with compensated or decompensated cirrhosis or hepa-
tocellular carcinoma tend to have worse HRQoL.2-6 However, it 
is less clear whether patients with chronic HBV infection without 
cirrhosis or cancer have worse HRQoL compared to the general 
population.2,5,7-11 Studies have also inadequately accounted for dif-
ferent phenotypes of chronic hepatitis B, such as subgroups who 
are immune tolerant, have active disease or are inactive HBsAg car-
riers.12 The majority of studies of HRQoL in patients with chronic 
HBV infection have been conducted in Asia, the Middle East or 
Europe, where sociocultural differences likely impact study find-
ings, making generalisability to North American cohorts challeng-
ing. Previous studies have also been limited by small sample sizes, 
inclusion of a minimal number of clinical or disease factors, and 
diverse patient populations that included both those with chronic 
hepatitis B and those with other types of liver diseases.
We hypothesised that investigating other salient patient-re-
ported outcomes may enhance our understanding of the physical 
and emotional sequelae of living with chronic hepatitis B including 
symptoms such as fatigue, depression and pruritus. Fatigue has been 
investigated in several studies, but is generally nonspecific and is 
affected by other, unrelated physical, mental and emotional fac-
tors.3,13,14 The paucity of data related to symptoms may be in part 
due to lack of instruments to adequately measure symptom severity 
in patients with chronic HBV infection.3 Measures of symptom pres-
ence and severity may be potentially more sensitive to variations in 
HBV disease markers or activity, compared to a broad nonspecific 
measure of HRQoL.
The Hepatitis B Research Network provides a unique opportu-
nity to evaluate symptom burden and HRQoL in a large multi-ethnic 
North American population.15 Our aims were to fully characterise 
symptoms and HRQoL in a cohort of adults with chronic HBV infec-
tion and to evaluate the association between the patient-reported 
outcomes and liver disease severity and clinical markers. We also 
examined the relationship among three patient-reported out-
come instruments: the Patient-Reported Outcomes Measurement 
Information System (PROMIS®) Fatigue 7a-item instrument, a 
multi-symptom checklist and the SF-36v2TM Health Survey.
2  | MATERIAL S AND METHODS
2.1 | Study design
The current analysis is a cross-sectional study of patients diag-
nosed with chronic HBV infection and enrolled in the Hepatitis B 
Research Network Adult Cohort study. The Hepatitis B Research 
Network is a consortium of investigators from 21 geographically 
diverse adult clinical centres across the United States and Canada 
funded by a cooperative agreement between the principal inves-
tigators and the National Institute of Diabetes and Digestive and 
Kidney Diseases of the National Institutes of Health. All protocols 
were approved by the Steering Committee and the Institutional 
Review Boards or Research Ethics Boards of the participating 
sites. All participants provided written informed consent. The 
Hepatitis B Research Network Adult Cohort Study is registered on 
ClinicalTrials.gov (NCT01263587).
2.2 | Participants
The Hepatitis B Research Network Adult Cohort Study enrolled 
2,032 adults with chronic hepatitis B not on any HBV therapy, from 
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2011 to 2018. After excluding 12 participants who tested HBsAg 
negative at the central laboratory and one participant adjudicated 
for hepatocellular carcinoma at enrollment, there were 2,019 HBsAg 
positive eligible participants (Figure 1). In addition, participants were 
excluded from this analysis if they had acute HBV infection, co-
infection with human immunodeficiency virus, hepatitis C virus or 
hepatitis D virus, were pregnant or were on HBV therapy within the 
6 months before completing the patient-reported outcome instru-
ments, or were unable to speak or read English or Spanish. The final 
analytic sample included 876 study participants age 18 or older who 
completed all three patient-reported outcome instruments (available 
in English or Spanish) at the same research visit and who were not re-
ceiving HBV therapy for the prior 6 months. Each participant's first 
assessment of all three patient-reported outcome instruments was 
used in this analysis.
2.3 | Patient-reported outcome measures
2.3.1 | Symptom checklist (SCL)
The SCL is a 10-item instrument initially developed by the National 
Institute of Diabetes and Digestive and Kidney Diseases to evalu-
ate the symptoms of chronic hepatitis C. Participants were asked, 
‘During the last month, how much have you been bothered by the fol-
lowing symptom: fatigue, itching, pain over liver, irritability, depres-
sion/sadness, nausea, poor appetite, weight loss, dark urine, jaundice’. 
For each symptom, the participant marked a box to indicate how 
bothered they were by the symptom in the last month: None at all 
(0), A little bit (1), Moderately (2), Quite a bit (3) or Extremely (4). If 
they did not have the symptom, they marked ‘None at all’. A total 
SCL score (T-SCL) was then created by summing the 10 symptom 
scores, with a possible range from 0 to 40, with higher scores in-
dicating worse symptoms. T-SCL was used as a measure of total 
symptom burden.
2.3.2 | PROMIS® fatigue 7a
The PROMIS Fatigue 7a-item instrument consists of seven questions 
that assessed the experience of fatigue and interference of fatigue 
on daily activities over the past 7 days.16,17 Participants respond on 
a 5-point ordinal scale (Never, Rarely, Sometimes, Often and Always) 
to the following questions: ‘In the past 7 days, how often did you feel 
tired? How often did you experience extreme exhaustion? How often did 
you run out of energy? How often did your fatigue limit you at work (in-
clude work at home)? How often were you too tired to think clearly? How 
often were to too tired to take a bath or shower? How often did you have 
F I G U R E  1   Study flow chart
Acute HBV n = 65
HBRN Adult Cohort
HBsAg(+)
n = 2032 participants
Exclusion based on central lab and
adjudication results at enrollment (n = 13)
n = 12 HBsAg(–) central lab results






Analytic sample n = 876
Excluded 18 HBsAg loss paticipants
n = 153 currently on or within 24 weeks of prior 
HBV treatment washout period
n = 41 currently pregnant or within 24 weeks of
prior pregnancy
n = 379 do not speak English or Spanish for 
PROMIS Fatique
n = 471 do not reach Week 48 visit for PROMIS
Fatique
n = 151 did not complete all three PROs
(8 participants fall into both groups.)
Excluded 186 paticipants
Excluded 771 paticipants who did not have a
study visit with completion of Fatique, symptoms,
and HRQoL (FSQ) assessments.
had at least 1 visit with all FSQ
Exclusions for other liver diseases
(n = 103)
Use the first available FSQ for the
cross-sectional analysis:
(7 Participants fall into more than 1
groups.)
n = 3 HIV
Week 48: 843 (78%)
Week 96: 1 (0%)
Week 144: 181 (17%)
Week 240: 54 (5%)













n = 36 HCV
n = 71 HDV
460  |     EVON Et al.
enough energy to exercise strenuously’. The total raw score is trans-
lated into a standardised T-score, with a mean of 50 and a standard 
deviation of 10. Higher scores indicate worse fatigue.
2.3.3 | SF-36v2™ health survey
The SF-36 is a widely used, generic measure o HRQOL.18,19 The 
SF-36 consists of items that load on eight subscales, which then can 
be combined into two summary scores, a physical component sum-
mary (PCS) and a mental component summary (MCS). The PCS and 
MCS are converted to T-scores based on population-based norms 
with each scale having a mean score of 50 and standard deviation 
of 10. Higher scores indicate better physical and mental health.
2.4 | Sociodemographic covariates
The following variables collected at the baseline visit into the cohort 
study were used in these analyses: age, sex, race, place of birth and 
education.
2.5 | Clinical and virological covariates
The following clinical and virological data collected at the same visit 
as the patient-reported outcomes instruments were used to evalu-
ate factors associated with the patient-reported outcomes: serum 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
AST-platelet ratio index (APRI), albumin, cirrhosis status, HBV 
phenotypes, HBV DNA (log10 IU/mL), HBeAg (positive, negative), 
quantitative HBsAg (qHBsAg log10 IU/mL), number of medical co-
morbidities (0,1,2+) and number of medications (0,1,2+). The upper 
limit of normal for ALT was 30 U/L for males and 20 U/L for females. 
The HBV phenotypes were defined based on HBeAg status and 
HBV DNA and ALT levels as previously defined by the Hepatitis B 
Research Network.12 The definitions used were as follows: Inactive 
carriers had HBsAg without HBeAg, normal ALT levels (≤1upper 
limit of normal) and no or low HBV DNA levels (≤10,000 IU/mL). 
Immune-active chronic hepatitis B was defined by the presence of 
HBsAg and elevated levels of ALT (>1 upper limit of normal) and HBV 
DNA ≥100,000 IU/mL in those with HBeAg and >10,000 IU/mL in 
those without HBeAg. Immune-tolerant chronic hepatitis B was de-
fined by the presence of HBeAg and HBV DNA ≥100,000 IU/mL in 
serum, with normal ALT levels (≤1 upper limit of normal). Patients 
not fitting into any of these three patterns were classified as having 
an ‘Indeterminate’ HBV phenotype.
2.6 | Statistical analyses
Categorical data were summarised with frequencies and percent-
ages and continuous data were summarised as median (25th and 
75th percentiles). To evaluate the relationships among four patient-
reported outcome scores (T-SCL, PROMIS Fatigue, SF-36 MCS, 
SF-36 PCS), each total score was analysed as a continuous measure. 
Ordinal variables for each of the 10 SCL symptoms on a 5-point 
ordinal scale were also created. Distribution of each outcome score 
was summarised using histograms. We computed Spearman corre-
lation coefficients between the four outcome scores and between 
each outcome measure and continuous covariates. Unadjusted 
and adjusted associations between the outcome scores and de-
mographics, HBV disease markers or clinical features were investi-
gated using multiple linear regression model for Fatigue, MCS and 
PCS; negative binomial regression was used for T-SCL outcome due 
to its right-skewed nature. We first accounted for sociodemograph-
ics (sex, age, race, education) in the multivariable model and used 
stepwise regression models for variable selection based on Schwarz 
Bayesian Information Criterion. The criterion for both entry and re-
moval from the models was with P < .05. P values were adjusted 
for multiple comparisons across four outcome measures in multi-
variable models using the Bonferroni-Holm method. Exploratory 
regression models were conducted to determine if symptoms (total 
and individual) were independent predictors of MCS and PCS and 
could predict additional variation in MCS and PCS, after control-
ling for the covariates in the initial regression models. All analyses 
conducted in statistical software packages SAS (version 9.4; SAS 
Institute Inc, Cary, NC) and R (version 3.5.3; R Foundation for 
Statistical Computing, Vienna, Austria). All tests were two-sided 
and a p value < 0.05 was considered statistically significant.
3  | RESULTS
3.1 | Study flowchart
Of 2019 eligible HBsAg-positive adult participants enrolled in 
the Hepatitis B Research Network cohort study, 876 patients 
met inclusion criteria for the current analysis (Figure 1). Patients 
(n = 168) were excluded who had acute HBV (n = 65) or co-infected 
with human immunodeficiency virus, hepatitis C virus or hepati-
tis D virus (n = 103); 771 participants were excluded who did not 
have complete outcome measure data at any time point, and 186 
patients were excluded for being on HBV treatment or pregnant 
within 24 weeks prior to outcome assessments. The majority 
(78%) of patients included in this analysis completed all PROs at 
week 48 of entry into the cohort study, followed by 17% at week 
144, and 5% at week 240.
3.2 | Participant characteristics
The characteristics of the 876 participants are summarised in Table 1. 
The median age was 42 years. Men and women were equally repre-
sented. Patients were predominantly Asian (73%) and 80% were born 
outside of the United States and Canada. The majority (59%) were 
     |  461EVON Et al.
college educated or greater. For HBV phenotype, 28% were consid-
ered inactive carriers, 30% had active disease (15% with HBeAg and 
15% without HBeAg), 3% were immune tolerant and 39% were des-
ignated as ‘indeterminate’. ALT levels were raised (> 1 upper limit of 
normal) in 64% of participants but were largely in the range of one 
to three times the upper limit of normal. HBV DNA was quantifiable 
(≥20 IU/mL) in 92% of patients and the median HBV DNA level was 3.4 
log10 IU/mL and majority (81%) had HBeAg-negative status. Only 2% 
of participants had APRI scores ≥1.5 suggestive of advanced fibrosis 
and less than 1% (n = 13) had known cirrhosis. The majority of patients 
(74%) had no medical comorbidities; only 10% had two or more comor-
bidities. The majority (76%) were not taking concomitant medications.
3.3 | Distribution of study outcomes
On a scale of 0 to 40, the mean T-SCL score was 3.1 (range: 0-26) 
(Figure 2). A significant floor effect was observed with 24.7% 
(n = 216) of patients reporting no symptoms of liver disease. Out of a 
possible range from 29.4 to 83.2, the mean PROMIS Fatigue T-score 
was 46.8 (range: 29.4−72.9), which is lower (better) than the mean of 
the general population (defined as a T-score of 50). Out of a possible 
range from 0 to 100, the MCS mean was 52.2 and the PCS mean was 
TA B L E  1   Demographic and clinical characteristics of 
participants
Variables All (n = 876)











Education level n = 870
Below Bachelor 357 (41%)
Bachelor or Higher 513 (59%)
Place of birth n = 874
Outside of the US/Canada 697 (80%)
In the US/Canada 177 (20%)
Phenotype n = 809
Immune tolerant 24 (3%)
HBeAg + CHB 118 (15%)
HBeAg- CHB 122 (15%)
Inactive carrier 226 (28%)
Indeterminant 319 (39%)
ALTxULN (male = 30, female = 20 U/L) n = 844
Median(25th:75th) 1.2 (0.9:1.7)
Min:Max 0.3:37.4
ALTxULN n = 844
≤1 ULN 302 (36%)
>1-3 ULN 480 (57%)
>3-5 ULN 40 (5%)
>5 ULN 22 (3%)
ASTxULN (laboratory-specific ULN) n = 842
Median(25th:75th) 0.7 (0.5:0.9)
Min:Max 0.3:14.1
ASTxULN n = 842
Normal AST 701 (83%)
Abnormal AST 141 (17%)
HBeAg n = 835
Negative 675 (81%)
Positive 160 (19%)
HBV DNA (log10 IU/mL) n = 868
Median(25th:75th) 3.4 (2.5:5.0)
Min:Max <LLOD: 9.5
Quantifiable HBV DNA n = 868
(Continues)
Variables All (n = 876)
≥ 20 IU/mL 802 (92%)
Quantitative HBsAg (log10 IU/mL) n = 823
Median(25th:75th) 3.4 (2.6:4.1)
Min:Max <LLOD: 5.5
Albumin (g/dL) n = 823
Median(25th:75th) 4.3 (4.1:4.5)
Min:Max 3.1:5.4




Cirrhosis prior/at PRO visit
No 863 (99%)
Yes 13 (1%)








Note: LLOD: Lower limit of detection (HBV DNA = 10 IU/mL = 1 log10 
IU/mL, quantitative HBsAg = 0.05 IU/mL= −1.3 log10 IU/mL)
TA B L E  1   (Continued)
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53.7, which were both higher (better) than the general US population 
norms (T-score of 50).
Figure 3 displays the cumulative frequency for each of the 10 symp-
toms from the SCL instrument. Many patients indicated the absence of 
symptoms. Fatigue was the most frequent symptom with 60% of patients 
reporting fatigue that was ‘a little bit’ to ‘extremely’ bothersome, followed 
by irritability (32%) and itching (32%). Only 2% of patients reported jaun-
dice. Most symptoms were rated only as ‘A little bit’ bothersome; rarely 
were symptoms rated ‘Quite a bit’ or ‘Extremely’ bothersome.
3.4 | Associations among patient-reported outcome 
instruments
The bivariate correlations among the MCS T-score, PCS T-score, 
PROMIS Fatigue T-score, T-SCL and the 10 symptom sub-scores gen-
erally ranged from r = 0.20 to 0.50 (Figure S1). PCS was moderately 
correlated with PROMIS Fatigue (r = 0.40) and T-SCL (r = 0.40). MCS 
was strongly correlated with SCL-Depression/Sadness item (r = 0.60), 
overall T-SCL score, SCL-Fatigue and PROMIS Fatigue (all r's = 0.50). 
PROMIS Fatigue was moderately correlated with SCL-Depression/
Sadness, SCL-Irritability and SCL-Fatigue (r's = 0.40-0.50) in addition 
to the MCS and PCS. Interestingly, the PROMIS Fatigue 7-item instru-
ment and the one-item SCL-Fatigue question had similar magnitudes of 
association with the other outcome scores. We observed a direct, linear 
relationship between worsening of PROMIS Fatigue T-scores and SCL-
Fatigue levels from ‘None’ through ‘Extremely’ bothersome (Figure S2).
3.5 | Bivariate associations between patient-reported 
outcomes and HBV laboratory and clinical markers
Bivariate correlations between the four outcome scores and all HBV 
covariates were almost nonexistent to small (range: r = 0.0 to 0.20) 
F I G U R E  2   Distribution of each patient-reported outcome measure. Higher scores in the physical component summary score and mental 
component summary score indicate better physical and mental health. Higher scores in Fatigue indicate more fatigue. Higher Total Symptom 
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Mean (SD): 3.1 (3.8)
Median (25th, 75th): 2 (1,4)
Min - Max: 0 - 26
95% Cl for the mean: 2.9-3.4
Mean (SD): 46.8 (7.6)
Median (25th, 75th): 45.8 (41.9, 52.2)
Min - Max: 29.4-72.9
95% Cl for the mean: 46.2-47.3
Mean (SD): 53.7 (6.8)
Median (25th, 75th): 55.7 (51.2, 58.4)
Min - Max: 22.1-67.5
95% Cl for the mean: 53.3-54.2
Mean (SD): 52.2 (8.6)
Median (25th, 75th): 54.5 (48.6, 58)








95% Cl for the mean: 51.6-52.8
Total symptom score (0-40)






















Fatigue T - score (29.4-83.2)
Physical Component Summary (PCS) T-scoreMental Component Summary (MCS) T-score
Total symptom score (T-SCL) Fatigue T - score
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(Figure S3). HBV phenotype, HBeAg and HBV DNA did not correlate 
significantly with any of the outcome measures. Apart from the small 
correlations between PCS and a higher number of comorbidities and 
medications (r = 0.20), all other correlations with HBV laboratory 
tests or clinical markers were negligible.
3.6 | Unadjusted and adjusted associations between 
patient-reported outcome measures with HBV disease 
markers and demographic characteristics
Unadjusted associations between each outcome score and demo-
graphics, clinical and laboratory covariates are provided in Table S1. 
Female sex, lower education, abnormal AST, APRI >1.5 and a higher 
number of comorbidities were most frequently associated with 
worse outcome scores.
For the multivariable analyses, we first accounted for sociode-
mographics (sex, age, race, education), then used stepwise regres-
sion models for variable selection from the following covariates: 
HBV phenotype, ALT, AST, HBeAg, HBV DNA, albumin, APRI, cir-
rhosis, comorbidities and concomitant medications. APRI and a 
higher number of comorbidities independently predicted PROMIS 
Fatigue and the PCS score (See Table 2). APRI was selected for 
T-SCL. None of the clinical variables were selected for MCS.1
Participants who had APRI >1.5 reported 7.73 points worse Fatigue 
(95% CI: 3.89, 11.56), 9.31 points worse PCS (95%CI: −12.56, −6.06) 
and 165% worse total symptom burden (mean ratio: 2.65; 95%CI: 1.54, 
4.56) compared to those with APRI ≤0.5. Participants who had two or 
more comorbidities reported 3.02 points worse Fatigue (95%CI: 0.99, 
5.06) and 3.97 points worse PCS scores (95%CI: −5.70, −2.25).
A few sociodemographic variables were also associated with 
worse outcome scores (Table 2). Females had 3.16 point worse 
Fatigue (95%CI: 2.02, 4.30), 1.93 points worse MCS (95%CI: −3.23, 
−0.64), 0.98 points worse PCS (95%CI: −1.94, −0.02) and 30% worse 
total symptom burden (mean ratio: 1.30; 95%CI: 1.09, 1.55) compared 
to males. Compared to Asians, Black and White patients reported 
37% (mean ratio: 1.37; 95%CI: 1.05, 1.78) and 38% (mean ratio: 1.38; 
95%CI: 1.06, 1.82) worse total symptom burden. Participants with 
lower education had 1.61 points worse Fatigue (95%CI: 0.43, 2.79) 
and 1.23 points worse PCS scores (95%CI: −2.23, −0.23). Collectively, 
the covariates selected in each regression model only explained 4% 
of the variation in mental health, 17% of the variation in physical 
health, 10% of the variation in Fatigue, and 7% of the variation in 
total symptom burden.
3.7 | Exploratory analyses of symptoms predicting 
physical and mental health
Given the low explanatory power of the original regression models 
to predict PCS and MCS, yet the moderate correlations observed be-
tween symptom scores and PCS and MCS, we speculated that adding 
1 Since APRI scores are calculated using AST and platelet count, we investigated removal 
of APRI from the models and adding platelet count. Abnormal AST was selected for three 
of four PROs. However, the original multivariable model including APRI was still a better 
fit for the data, therefore, the remaining results are based on the original modelling plan.
F I G U R E  3   Composition of symptoms 
ranging from ‘None’ to ‘Extremely’. 
Subcategories with less than 1% are not 
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T-SCL to the regression models might help explain additional variability 
in MCS and PCS scores, over and above the initial set of covariates. 
Table 3 shows that T-SCL independently explained 41% of the variation 
in MCS, totalling 44% explanatory power when added to the other co-
variates in the model. Likewise, T-SCL independently explained 22% of 
the variation in PCS scores, totalling 34% of the variation in PCS when 
added to the original covariates in the model. Thus, T-SCL improved 
the prediction of MCS from 4% to 44% and PCS from 17% to 34% 
when added to the original models. We also examined the unique con-
tribution of each symptom to the original prediction models (Table 3). 
Most notably, the Depression/Sadness item from the SCL predicted 
additional 50% of the variation in MCS scores. For every categorical 
increase in depression/sadness (eg from ‘A little bit’ to ‘Moderately’), a 
patient's MCS score decreases by 8.10 points. For PCS, the SCL items 
for Fatigue, Nausea and Pain over the Liver each contributed 10%-14% 
of additional variation to the orginal models. For example, for every 
categorical increase in Fatigue (eg from ‘Moderately’ to ‘Quite a Bit’), a 
patient's PCS score decreased by 2.83 points.
3.8 | Assessment of HBV disease activity and stage
Assessment of disease severity focuses upon two separate fea-
tures: disease activity (grade) and disease stage (fibrosis).20 Disease 
TA B L E  2   Multivariable models for fatigue, mental component summary score, physical component summary score, and total symptom 
score (n = 707)
Predictors
Patient-reported outcomes (PROs)
PROMIS Fatigue score 














Age, per 10 years P = .94 P = .20 P < .01 P = .95
 0.18 (−0.31, 0.66) 0.52 (−0.03, 1.07) −1.19 (−1.60, −0.78) 1.00 (0.93-1.07)
Sex P < .01 P = .01 P = .046 P = .01
Male Reference Reference Reference Reference
Female 3.16 (2.02, 4.30) −1.93 (−3.23, −0.64) −0.98 (−1.94, −0.02) 1.30 (1.09-1.55)
Race P = .32 P = .19 P = .72 P = .049
Asian Reference Reference Reference Reference
Black −2.03 (−3.78, −0.28) −0.44 (−2.44, 1.57) 0.05 (−1.45, 1.54) 1.37 (1.05-1.78)
Other/Mixed −0.20 (−3.25, 2.85) −1.40 (−4.86, 2.07) 0.44 (−2.14, 3.02) 1.39 (0.88-2.19)
White −0.40 (−2.21, 1.41) −2.75 (−4.81, −0.69) 0.87 (−0.67, 2.40) 1.38 (1.06-1.82)
Education P = .03 P = .36 P = .046 P = .50
Below Bachelor 1.61 (0.43, 2.79) −0.92 (−2.26, 0.42) −1.23 (−2.23, −0.23) 1.06 (0.89-1.27)
Bachelor or Higher Reference Reference Reference Reference
APRI (AST-platelet ratio 
index)
P < .01 P = .16 P < .01 P < .01
≤0.50 Reference Reference Reference Reference
>0.50-1.50 1.03 (−0.40, 2.46) 0.10 (−1.53, 1.73) −0.98 (−2.20, 0.23) 1.29 (1.04-1.61)
>1.50 7.73 (3.89, 11.56) −4.20 (−8.57, 0.16) −9.31 (−12.56, −6.06) 2.65 (1.54-4.56)
Number of 
comorbidities
P = .02 P = .12 P < .01 P = .21
0 Reference Reference Reference Reference
1 −0.17 (−1.77, 1.43) 0.52 (−1.31, 2.34) −0.10 (−1.45, 1.26) 1.10 (0.86-1.39)
2+ 3.02 (0.99, 5.06) −2.45 (−4.76, −0.13) −3.97 (−5.70, −2.25) 1.30 (0.97-1.76)
Model R2 R2 = 0.10 R2 = 0.04 R2 = 0.17 R2 = 0.07
Note: P values were adjusted for multiple comparisons across four patient-reported outcomes using the Bonferroni-Holm method.
aMultiple linear regression was used to estimate the adjusted association between each predictor and each patient-reported outcome respectively. 
If a 95% confidence interval for a mean difference does not include 0, the mean of Fatigue, Mental Component Summary score, Physical Component 
Summary score is significantly different between groups or per unit change in a continuous predictor. R2 is the proportion of the response patient 
reported outcome variable variation that is explained by a linear model. 
bNegative binomial regression was used to estimate the adjusted association between each predictor and total symptom score. If a 95% confidence 
interval (CI) for a mean ratio does not include 1, the mean of T-SCL is significantly different between groups or per unit change in a continuous 
predictor. 
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activity is the degree of inflammation, and can worsen, improve or 
resolve. Disease stage is reflected in degree of fibrosis and cirrho-
sis, factors that usually progress and do not resolve. We aimed to 
understand how much symptoms or health-related quality of life 
may be associated with disease activity and disease stage. Using ALT 
and AST to reflect disease grade and APRI to reflect disease stage, 
we generally found that outcomes were worse with more advanced 
stages of disease (APRI >1.50) and affected by more severe disease 
activity, and generally only at the extremes of both. The different 
ranges of the 10 symptoms at different levels of APRI are shown 
in Figure S4 and at different levels of ALT in Figure S5. Thus, the 
10 symptoms correlated with APRI, but the association was largely 
with APRI >1.50 and with symptoms that were ‘Moderate’ or worse, 
rather than ‘A little bit’. Similarly, ALT elevations correlated with 
symptoms, but only at the extremes of ALT (>5 upper limit of nor-
mal) and with ‘Moderate’ or worse symptoms, as opposed to ‘A little 
bit’. Thus, symptoms described as ‘A little bit’ were generally nonspe-
cific and were not more frequent with more severe disease activity 
or advanced stage. In contrast, describing symptoms as ‘Moderately’, 
‘Quite a Bit’ or ‘Extremely’ bothersome was associated with more se-
vere disease activity or advanced stage of disease.
4  | DISCUSSION
Findings from previous studies of quality of life in patients with HBV 
have been difficult to extrapolate to patients living in the United 
States and Canada due to underlying sociodemographic, regional and 
cultural influences that may exert strong effects on HRQoL scores. 
Additionally, symptom burden associated with HBV has been under-
studied, but may be important to understanding patients’ experiences 
with living with HBV, a highly infectious and frequently stigmatising 
liver disease. In this cross-sectional analysis, we included a large multi-
ethnic North American cohort from 21 adult liver centres across the 
United States and Toronto. This cohort was predominantly of Asian 
ethnicity, college educated, asymptomatic and healthy; a very low 
proportion had cirrhosis (<1%), multiple comorbidities or were tak-
ing any medications (<25%). Nevertheless, interesting findings were 
observed. On average, this relatively healthy cohort without severe 
liver disease experienced very few HBV-related symptoms and had 
uncompromised quality of life. Secondly, HBV virologic markers 
such as HBV DNA, quantitative HBsAg and HBV phenotypes were 
not independently associated with symptoms or quality of life. High 
APRI score, reflecting more advanced liver disease stage was the only 
important clinical variable significantly associated with worse symp-
toms and quality of life. Finally, we discovered a robust relationship 
between symptoms and physical and mental quality of life, highlight-
ing the importance of measuring HBV-related symptoms in future re-
search and in clinical practice, as some symptoms may play a crucial 
role in the mental and physical well-being of patients living with HBV.
This North American sample had, on average, equal or bet-
ter HRQoL and fatigue scores compared to US general population 
norms. This finding may be due to characteristics of the cohort such 
as absence of cirrhosis, fewer comorbidities or concomitant medica-
tions, and higher levels of education and employment compared to 
population norms.21 However, our findings are consistent with one 
Canadian study10 and one recent international Phase II clinical trial22 
which found no differences in HRQoL between noncirrhotic HBV 
patients and population norms. Although few studies have investi-
gated symptoms as a primary endpoint, our findings are consistent 
with a Persian study which also found a low prevalence of symptoms 
and mostly reported as mild and nondistressing.3
High APRI score was associated with worse PROs scores. This 
finding is consistent with several other studies documenting worse 
PROs in patients with more severe liver disease.2,3,5,23 However, it 
should be noted that APRI is most sensitive for cirrhosis detection 
in patients with chronic hepatitis C or non-alcoholic fatty liver dis-
ease, compared to HBV patients due to a greater degree of variabil-
ity in untreated HBV patients.24 While the definitions of advanced 
liver disease (eg compensated, decompensated, hepatocellular car-
cinoma, Child-Pugh scores) have varied among studies, most have 
shown worse HRQoL and symptoms among patients with decom-
pensated cirrhosis or liver cancer. In the current study, less than 1% 
of patients were diagnosed with cirrhosis by expert adjudication and 
only 2% had APRI scores >1.50. These patients experienced five 
symptoms (on average) and many experienced moderate to severe 
fatigue, irritability, pruritus and depression (Figure S4). Additionally, 
participants with elevated ALT (>5 upper limit of normal) also ex-
perienced more symptoms (Figure S5). Therefore, clinicians should 
suspect advanced liver disease or high disease activity in patients 
complaining of moderate to extremely bothersome symptoms.
While none of the other HBV laboratory or clinical markers were 
associated with PROs, we identified other factors that identify pa-
tient subgroups at risk for worse PROs. Patients with more comor-
bidities may be at risk for worse fatigue and physical health, a finding 
consistent with other studies.3,10,25 Female patients are also at risk for 
worse fatigue, mental health, physical health and report 30% more 
symptoms, compared to men; also consistent with prior studies.9,22 
We also discovered that Black and White patients report approxi-
mately 40% more symptoms than Asians and that lower education 
is associated with more fatigue and worse physical health. Taken to-
gether, these data suggest that future research endeavours which 
seek to examine factors associated with HRQOL and symptoms in 
HBV populations should include advanced liver disease, number of 
comorbidities and certain sociodemographics in statistical model-
ling.26 Equally important to recognise, however, is that collectively 
these factors explained very little variation in self-reported physical 
(17%) and mental health (4%), making it incumbent upon future in-
vestigations to evaluate additional factors that might help explain 
physical and mental health in HBV populations; for instance, other 
HBV studies have found age, sex, income level, body mass index and 
psychiatric comorbidity predictive of HRQoL scores.2,3,10,22,25
Symptom burden has rarely been explored in HBV patients and 
none in North American cohorts.3,14,27 Given this shortcoming, we 
explored the utility of adding symptom burden (T-SCL score) and 
individual symptom scores to predict mental and physical health. 
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A well-known conceptual model by Wilson and Cleary describes a 
causal model whereby biological causes (eg virus and cirrhosis) may 
lead to physical or mental symptoms (defined as a ‘patient's percep-
tion of an abnormal physical, emotional or cognitive state’), which 
in turn, affects functioning (physical, social, role,and psychological), 
health perceptions and overall quality of life.28 Consistent with this 
model, we discovered that when the T-SCL score was added to the 
initial regression models, we were able to substantially increase pre-
diction of mental health from 4% to 44%. Moreover, one item from 
the SCL instrument (‘How bothered are you by depression or sad-
ness’) predicted mental health functioning better (R2 = 0.54) than 
the complete 10-item survey. Future studies seeking to understand 
mental health status should include depression/sadness symptom 
measurement which will have clinical implications for patient care. 
Likewise, adding T-SCL to the models to predict self-reported physi-
cal health QOL improved predictability from 17% to 34%.
Interestingly, both the 7-item PROMIS Fatigue and the one-
item SCL-Fatigue were equally correlated with mental health 
status and with most individual symptoms, suggesting that they 
might perform equally well in future studies. The advantage of the 
PROMIS® Fatigue instrument is that these measures were rigor-
ously developed and validated for use across general and medical 
populations.16,17 However, a one-item fatigue question in a 10-item 
multi-symptom instrument might also be attractive when con-
strained by time or resources. Subsequent studies might explore 
the psychometric properties of the National Institute of Diabetes 
and Digestive and Kidney Diseases Symptom Checklist for use in 
the HBV population.
This is the largest, most comprehensive assessment of patient-re-
ported outcomes in a population of patients with HBV; nonetheless 
the study has limitations. Considering the low proportion of cirrhotic 
patients, our findings cannot be generalised to patients with more 
severe liver disease. The low rate of cirrhosis in this cohort may in 
part reflect the requirement of enrolling only untreated patients into 
the HBRN cohort study.15 As HBV therapy is recommended only in 
patients who have suspected moderate inflammation or fibrosis, it is 
not surprising that this untreated cohort had milder liver disease. In 
addition, the sensitivity and specificity of the APRI score for detect-
ing advanced fibrosis in HBV patients are limited.24 Furthermore, a 
more accurate assessment of disease staging such as liver elastogra-
phy or liver biopsy was not undertaken prior to or at the same visit 
that these four PROs were collected in the majority of patients (only 
4% and 11% had undergone these procedures respectively). The 
PROMIS Fatigue survey was not collected in over 350 non-English/
non-Spanish speaking patients because validated translations of 
this instrument were not available at study initiation. Finally, North 
American population controls of Asian ethnicity, the main ethnic 
group in our HBV cohort, were not available for the PROMIS® or 
SF-36 instruments, but it is possible that these patients have better 
PRO scores compared to population controls. Future studies should 
be conducted to evaluate the relevance and understandability of 
these patient-reported outcomes measures in order to adapt them 
Models
Mental component  
summary (MCS)
Physical component  
summary (PCS)
Mean difference  
(95% CI)a R2
Mean difference  
(95% CI)a R2
Multivariable model (MV)b – 0.04 – 0.17
MV + T-SCL −1.46 (−1.59, −1.33) 0.44 −0.77 (−0.88, −0.65) 0.34
MV + SCL-Fatigue −4.91 (−5.50, −4.33) 0.31 −2.83 (−3.30, −2.36) 0.31
MV + SCL-Irritability −6.05 (−6.74, −5.35) 0.33 −2.30 (−2.90, −1.71) 0.23
MV + SCL-Itching −2.99 (−3.75, −2.23) 0.12 −1.97 (−2.54, −1.40) 0.22
MV + SCL-Depression/
Sadness
−8.10 (−8.68, −7.52) 0.54 −2.10 (−2.71, −1.50) 0.22
MV + SCL-Poor appetite −5.36 (−6.35, −4.37) 0.18 −2.79 (−3.55, −2.02) 0.23
MV + SCL-Weight loss −2.67 (−3.90, −1.44) 0.07 −1.58 (−2.50, −0.66) 0.18
MV + SCL-Nausea −4.92 (−6.13, −3.71) 0.12 −4.65 (−5.53, −3.77) 0.28
MV + SCL-Pain over liver −4.80 (−5.98, −3.62) 0.12 −4.36 (−5.22, −3.50) 0.27
MV + SCL-Dark urine −5.40 (−6.82, −3.97) 0.11 −4.24 (−5.29, −3.18) 0.24
MV + SCL-Jaundice −6.19 (−8.80, −3.58) 0.07 −2.90 (−4.86, −0.94) 0.18
aGeneralized linear regression was used to estimate the association between predictors and each 
patient-reported outcome. If a 95% confidence interval does not include 0, there is a significantly 
difference in the mean of the mental or physical component summary score, per one-unit increase 
in total symptom burden or per one-level increase in each symptom checklist symptom. R2 is 
the proportion of the response in mental or physical component summary score variation that is 
explained by a linear model. 
bThe multivariable model included age per 10 years, sex, race, education, aspartate 
aminotransferase-platelet-ratio index (APRI), and comorbidities. 
TA B L E  3   Associations between 
symptoms and Mental Component 
Summary score (MCS) and Physical 
Component Summary score (PCS) 
(n = 707)
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for use in different ethnic populations such as this predominantly 
Asian population living the United States. Finally, other factors that 
might explain decrements in HRQoL were not collected (eg feeling of 
social stigma, sleep disturbance and health-related anxiety).
To conclude, untreated North American patients with HBV and 
generally mild liver disease report favourable HRQoL scores and 
minimal HBV-associated symptoms. Except for the presence of ad-
vanced liver disease , HBV disease or laboratory markers did not 
affect patients’ well-being, functioning, fatigue or other symptoms. 
The presence of moderate to extreme symptoms, especially fatigue, 
irritability, itch and depression/sadness may also signal the presence 
of advanced liver disease. As HBV is a dynamic disease, longitudinal 
studies are needed to better understand the evolution of symptoms 
and HRQoL with the natural history of HBV and also in the setting of 
HBV therapy.
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